The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested.
M ultiple sclerosis (MS) represents a disease with a high burden of morbidity and substantial impact on quality of life. 1, 2 Primary progressive MS (PPMS) accounts for 10% to 20% of MS and is characterized by a gradual decline in neurological function from the onset of symptoms. [2] [3] [4] [5] [6] A subset of patients with progressive-onset MS will also experience episodes of distinct clinical relapse, representing the previously described progressive-relapsing phenotype of MS (PRMS). 7, 8 In 2014, Lublin et al 7 proposed a reclassification of progressive-onset MS phenotypes in which PPMS and PRMS are categorized as a single phenotype under the umbrella of PPMS. This single phenotype can be further described by disease activity, defined as the presence or absence of either superimposed clinical relapses or new activity (gadolinium-enhancing or T2 lesions) on magnetic resonance imaging. Progressive-onset MS with and without superimposed relapse is associated with a reduced time to irreversible disability milestones; however, there is limited research to date identifying factors that contribute to this disability accrual. 9, 10 In particular, likely owing to the low prevalence of PRMS, the role of episodic inflammation in disability accumulation remains contested. [11] [12] [13] [14] [15] [16] While previous landmark cohort studies did not identify any association of superimposed relapse with disability outcomes in progressive-onset MS, findings of more recent research indicates that a subset of patients with a more rapidly deteriorating course may exist. [11] [12] [13] [14] [15] [16] Moreover, results of recent randomized clinical trials provide further support for the notion of a subset of patients with progressive-onset MS characterized by a greater degree of ongoing inflammatory activity. 17, 18 The implications of characterizing this subset of patients with progressive-onset MS include (1) identification of a subgroup of patients that may benefit from preexisting therapy, (2) recognition of inflammatory relapse as a disability modifier in design of future therapeutic trials, and (3) a better pathophysiological understanding of the interaction between relapse and progression, the 2 core phenomena of MS. 19 Hence, characterizing the clinical features of progressiveonset MS with and without relapse represents an area of unmet need. Our study used MSBase, a large international, observational cohort, to examine the association of superimposed relapses on disability accumulation in progressive-onset MS. 20 We first described the clinical characteristics of patients with progressive-onset with relapse vs those without. Following this, we evaluated the association between superimposed relapses and disability outcomes. Finally, we investigated the interaction between disease activity and disease-modifying therapy (DMT) in progressive-onset MS.
Methods

Ethics
The MSBase registry 20 (registered with WHO ICTRP, anzctr.org.au identifier: ACTRN12605000455662) was approved by the Melbourne Health Human Research Ethics Committee and the local ethics committees of participating centers (or exemptions were granted in accordance with local laws and regulations). If required, enrolled patients provided written informed consent.
Participants
Data from 44 449 patients from 117 centers in 36 countries were extracted from the MSBase registry in February 2017. The study followed the complete-case analysis principle. The inclusion criteria consisted of the diagnosis of definite PPMS or PRMS (according to 2005 or 2010 revised McDonald criteria  21,22 ), adult-onset disease, 3 or more visits with Expanded Disability Status Scale (EDSS) score recorded, more than 3 months between second and last visit, and availability of the minimum data set. The minimum data set requirements included date of birth, sex, MS course, and center; only patient data from centers contributing 10 or more patient records were included. Data entry into MSBase registry was near real time and was achieved through the iMed clinical record system or the MSBase online data entry portal. Data were collected between January 1995 and February 2017, and analyses began in February 2017. Data recorded in local databases before the launch of MSBase were merged into MSBase in 2004 or later. 20 Data quality was assessed prior to screening for inclusion and statistical analysis as per standard MSBase procedures (eTable 1 in the Supplement). 23 Lublin et al 7 have defined PPMS as with or without relapses, which replaced the previous diagnoses of PRMS and PPMS, respectively. For simplicity, we will use PRMS and PPMS as diagnostic categories throughout the remainder of the article and progressive-onset MS when describing both groups. Patients were categorized into the PRMS group based on the diagnosis of PRMS and/or progressive-onset MS with a recorded relapse in the data set; otherwise they were categorized as PPMS.
Disability was measured using the EDSS, with neurostatus certification required at each participating center to improve the reliability of clinical disability assessment. 24 Relapse was defined as the occurrence of new symptoms or exacerbation of existing symptoms persisting for at least 24 hours, in the absence of concurrent illness or fever, and occurring at least 30 days after a previous relapse. 25 MSBase protocol does not require quantifiable disability change or correlation on imaging to confirm relapse. Progression was defined as an increase in EDSS score by 1 step (1.5 steps if baseline EDSS score was 0, and 0.5 steps if baseline EDSS score was >5.5).
The primary outcome was a confirmed disability progression event, defined as increase in EDSS score by 1.5 steps if baseline EDSS score was 0, 1 step if baseline EDSS score was 1 to 5.5, and 0.5 steps if baseline EDSS score was 6 or greater. As multiple progression events were allowed per patient, periods of EDSS score progression were measured from each base visit, defined as the date of inclusion and 1 day after subsequent confirmed progression events. Expanded Disability Status Scale score was confirmed at a minimum of 3 months and sustained for the remainder of follow-up. 26 While EDSS scores irrespective of their association with relapse were eligible to establish disability progression, only EDSS scores recorded more than 30 days from onset of relapse could be used to confirm disability progression. Patients who did not reach end points were censored at the final eligible visit.
Statistical Analysis
Mean with 95% CIs or median with quartiles (first quartile to third quartile) were used to describe data distributions. Cohen d was calculated to determine effect size across PRMS vs PPMS groups. Multivariable models with mixed effects adjusted for annualized visit rate were fitted to analyze the association of superimposed relapse on the cumulative hazard of confirmed disability progression events (Andersen-Gill). In addition to MS group (PRMS or PPMS), sex, frequency of visits with EDSS scores, and proportion of follow-up on both DMT and immunosuppression were modeled as covariates. Age and EDSS scores were additionally modeled as time-dependent covariates, measured at each base visit. To account for centerspecific bias (including any differences in the years of patient inclusion) and within-patient dependence, we modeled center and patient identification as random effects. Proportional hazards assumption was assessed with Schoenfeld residuals and any violations corrected by introducing an interaction term with a time variable.
To identify any differential association of DMT with confirmed disability progression between groups, we subsequently introduced an interaction term between proportion of follow-up receiving DMT (per 10% follow-up time receiving DMT) and MS group to each model. Finally, to further characterize this potential interaction, we stratified each model according to MS group.
Two sensitivity analyses were performed to (1) exclude the role of relapse-related disability progression by excluding visits preceded by relapse within 12 months and (2) exclude boutonset progressive MS by selecting only patients with recorded relapses 30 days or more from symptom onset.
All statistical analyses were performed using R, version 3.3.2 (R Foundation for Statistical Computing). Mixed-effects models were fitted using the coxme package. Models were selected according to model validity, clinical relevance, and goodness of fit determined by the Akaike Information Criterion. All hypotheses were tested at a 2-tailed .05 level of significance.
Results
Patient Demographics
Prior to inclusion, progressive-onset disease represented 6.4% of patients with recorded MS course in the MSBase registry. Of the patients enrolled in the MSBase registry at time of data extraction, 1419 patients from 83 centers across 28 countries were eligible for analysis after the inclusion criteria were applied ( Figure 1 and Of the 553 patients in the PRMS group, 320 (58%) experienced a total of 864 recorded relapses during follow-up. The 
Primary Analysis
The preliminary univariable analysis unadjusted for confounding covariates revealed a lower risk of disability progression in patients with PRMS compared with PPMS (hazard ratio [HR], Figure 2 .
To further investigate the association between DMT and disease course, we incorporated an interaction term between the proportion of time receiving DMT and MS group into the multivariable model. The association between exposure to DMT (per 10% follow-up time spent receiving DMT) and likelihood of confirmed disability progression was dependent on allocation to PRMS or PPMS group (HR, 0.93; 95% CI, 0.90-0.97; P < .001).
Outcomes of the stratified models are outlined in Table 2 . In the PRMS cohort (n = 553), we observed a 4% relative decrease in the hazard of confirmed disability progression events for each 10% increment in persistence receiving DMT (HR, 0.96; 95% CI, 0.94-0.99; P = .01). This association was not seen in the PPMS cohort (n = 866; HR, 1.02; 95% CI, 0.99-1.05; P = .26). In addition, we observed that male sex (PRMS group: HR, 1.19; 95% CI, 1.00-1.40; P = .04; PPMS group: HR, 1.22; 95% CI, 1.07-1.39; P = .003) and EDSS score at each base visit (PRMS group: HR, 1.09; 95% CI, 1.04-1.14; P < .001; PPMS group: HR, 1.04; 95% CI, 1.00-1.08; P = .03) increased the likelihood of confirmed disability progression within PRMS and PPMS groups. We did not observe any association between age (PRMS group: HR, 1.00; 95% CI, 0.99-1.00; P = .40; PPMS group: HR, 1.00; 95% CI, 0.99-1.00; P = .14) or proportion of follow-up receiving immunosuppression (PRMS group: HR, 1.00; 95% CI, 0.98-1.03; P = .77; PPMS group: HR, 1.00; 95% CI, 0.96-1.03; P = .82) and likelihood of confirmed disability progression.
Sensitivity Analyses
The first sensitivity analysis, which excluded relapse-related disability progression, identified 1356 patients from the original cohort. When accounting for relapse-related progression, a reduced likelihood of confirmed disability progression in patients with PRMS vs those with PPMS was maintained (HR, 0.87; 95% CI, 0.77-0.98; P = .03) ( Figure 3A) . However, when stratified according to MS group (PRMS or PPMS), results of this sensitivity analysis revealed no association between proportion of follow-up time on DMT and cumulative hazard of disability progression in PRMS (HR, 1.10; 95% CI, 0.96-1.24; P = .16).
The second sensitivity analysis identified 436 patients with relapses that occurred later than the first 30 days of symptom onset. A reduced likelihood of disability progression in the PRMS group was maintained after excluding bout-onset progressive MS (HR, 0.83; 95% CI, 0.73-0.95; P = .006) ( Figure 3B ).
Discussion
In this study of 1419 patients from the international, observational MSBase cohort, we have demonstrated that the presence of superimposed relapse in progressive-onset MS is associated with a reduced progression of disability. Interestingly, we have shown that DMT reduces the likelihood of progression in progressive-onset MS with relapse but not in progressive-onset MS without relapse. The sensitivity analysis excluding disability progression events that were preceded by relapses showed that the association of DMT with disability progression is mediated through controlling relapse-related disability worsening. This suggests that relapses in progressiveonset MS, as a clinical correlate of episodic inflammatory activity, represent a positive prognostic marker and provide an opportunity to improve disease outcomes through prevention of relapse-related disability accrual. 
PRMS group
Multivariable Andersen-Gill model adjusted for multiple potential confounders of disease outcomes. More than 1 progressive event per patient was allowed. HR indicates hazard ratio. To date and to our knowledge, there are limited epidemiologic data describing the characteristics of progressiveonset MS with superimposed relapse vs without. The ratio of men to women in our study (1:1.19 in PRMS and 1:1.20 in PPMS) was consistent with previous studies describing the clinical characteristics of PPMS and those comparing PRMS with PPMS. 5, [10] [11] [12] 27, 28 Where previous research has identified no difference in age at onset between patients with vs without relapse, we demonstrated that patients with PRMS were younger at disease onset compared with those with PPMS. 12 This may be attributed to a reduced time to diagnosis due to the bout onset of the disease in a proportion of patients with PRMS.
Additionally, few studies have described the relapse characteristics of patients with PRMS, to our knowledge. 12, 13 Tullman et al 13 described a mean (SD) annualized relapse rate of 0.6 (0.8) in a cohort of 16 patients with PRMS. Our median annualized relapse rate of 0.15 (quartiles 0.08 to 0.26) is likely a conservative estimate, as it includes time from symptom onset prior to inclusion date. Consistent with previous findings, the domain most commonly affected by relapses was the motor system.
12,13
The role of superimposed relapse in disability accumulation in progressive-onset MS remains contested. [11] [12] [13] [14] [15] [16] Several recent studies have identified superimposed relapse as an independent determinant of disability accrual. 13,15,16 Conversely, other studies have identified no influence of superimposed relapse on the accumulation of disability in progressive-onset MS phenotypes. 11, 12, 14 Our study established a negative association between superimposed relapses in progressive-onset MS and the likelihood of confirmed disability progression, which can be attributed to an association of treatment in the PRMS but not the PPMS group. Additionally, the findings of our first sensitivity analysis suggest that, in the absence of treatment effect, patients with PRMS continue to have a reduced likelihood of disability progression compared with those with PPMS. These findings may indicate a difference in the underlying natural history of PRMS vs PPMS when accounting for relapse-related progression. A substantially greater proportion of patients with PRMS received DMT compared with PPMS (46% vs 21%). The relatively high proportion of patients with progressive-onset MS receiving DMT likely represents individual practices in tertiary centers, which we have accounted for by incorporating center as a random effect in our mixed-effects model. Persistence receiving DMT reduced the likelihood of progression in patients with PRMS, an association that was not observed in those with PPMS. This observation is in keeping with the outcomes of the INFORMS trial, which did not find any effect of fingolimod on 3-month confirmed disability progression in PPMS over 3 years. 29 Our own observational study extended this result to other DMT in patients with PPMS without superimposed episodic inflammatory activity. 30 This finding is also consistent with previous findings that patients with episodic clinical worsening or inflammatory changes on magnetic resonance imaging are more likely to respond to DMT. 17, 18, 31, 32 Furthermore, when relapse-related disability progression was excluded in a sensitivity analysis, the association of DMT in PRMS was no longer observed. Given that clinical relapse is seen as a clinical correlate of acute inflammatory changes, this finding suggests that DMT in progressive-onset MS mitigates acute episodic inflammation-associated disability accrual. 33 We confirmed the results of previous studies documenting male sex as a negative prognostic factor in PPMS. 9, 34, 35 Compared with the role of DMT, time receiving immunosuppression did not influence likelihood of disability progression. The finding that a higher EDSS score at baseline visit increases the risk of disability accrual in both patient cohorts may be inherent to the definition of progression, where a baseline EDSS score greater than 5.5 requires only a half-step increment. However, given that higher EDSS scores are relatively infrequent, this may also reflect the association of patients with a more severe disability trajectory as described by Signori et al.
31
Studies of observational data are subject to multiple biases. We have mitigated the impact of detection bias by adjusting the analyses for the frequency of recorded EDSS scores, which is representative of the frequency of clinical appoint- 
PRMS group
A, Exclusion of all visits that occurred within 12 months of preceding relapse was performed to exclude relapse-associated disability progression. B, Exclusion of bout-onset progressive multiple sclerosis (MS) was performed to identify the effect of ongoing relapses on disability progression in PPMS.
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Association of Inflammation and Disability Accrual in Progressive-Onset Multiple Sclerosis ments. We have accounted for confounding by sex and baseline EDSS score by incorporating these as covariates. The median duration between symptom onset and inclusion was similar for both PRMS and PPMS groups (Cohen d = 0.06). By modeling age as a time-dependent covariate from date of inclusion, we have concurrently adjusted for disease duration from inclusion. We have also controlled for center-specific management and within-patient dependence by incorporating center and patient identification as random effects within our models. Finally, we have shown that the reduced rate of disability progression remains present when excluding patients with bout-onset progressive MS.
Limitations
The principal limitation of this study is inherent in the use of the EDSS as a clinical measure of disability. We have enhanced reliability of disability measurement by requiring neurostatus certification from involved centers. 24 The proportion of patients with progressive-onset MS in our cohort (6.4% prior to exclusion criteria) was lower than previously documented.
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This may represent a level of underreporting of progressiveonset MS by clinicians and thus may impact negatively on the generalizability of results. Furthermore, the MSBase observational plan does not require quantifiable disability change to confirm relapse. We have attempted to minimize erroneous reporting through standardized quality assurance procedures as described elsewhere. 23 Magnetic resonance imaging as a marker of inflammatory activity may provide further insight into the role of DMTs in progressive-onset MS; however, to date, we are limited by availability of imaging data in this cohort.
Conclusions
In patients with progressive-onset MS, superimposed relapses are associated with a lower risk of confirmed disability progression. This is most likely attributed to differences in natural disease course as well as the preventive association of DMT on relapse-related disability accrual in patients with progressive-onset disease and superimposed relapse. These findings provide further evidence for a progressive-onset MS phenotype with acute episodic inflammatory changes, thereby identifying patients who may respond to existing immunotherapies. Relapse, as a clinical correlate of acute episodic inflammation in progressive-onset MS, therefore constitutes a prognostic marker and a treatment target. Further research is needed to characterize the role of acute episodic inflammation in progressive-onset disease, in particular incorporating evidence of inflammatory magnetic resonance imaging activity as a predictor of disease course. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. eTable 1. Data quality procedure  Duplicate patient records were removed.  Centres with <10 patient records were excluded.  Patients with missing date of birth were excluded.  MS onset dates after the MSBase data extract date were removed.  Patients with missing date of the first clinical presentation of MS were excluded.  The dates of MS onset and the first recorded MS course were aligned.  Patients with the age at onset outside the 0-100 range were excluded.  A logical sequence of the MS courses (e.g. clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS) was assured.  Entries with the initiation of progressive MS prior to its clinical onset of MS were excluded.  Visits with missing visit date or the recorded date before the clinical MS onset or after the date of MSBase data extract were removed.  EDSS scores outside the range of possible EDSS values were removed.  Duplicate visits were merged.  MS relapses with missing visit date or the recorded date after the date of MSBase data extract were removed.  Duplicate MS relapses were merged.  Relapses occurring within 30 days of each other were merged.  Visits preceded by relapses were identified and time from the last relapse was calculated for each visit.  Therapies were labelled as discontinued or continuing.  Therapies with erroneous date entries were removed (e.g. commencement date > termination date, commencement after the MSBase data extract date, commencement of disease modifying therapy before the year 1980).  MS disease modifying therapies were identified and labelled.  Duplicate treatment entries were removed.  Where multiple disease modifying therapies were recorded simultaneously, treatment end date of the previous therapy was imputed as the commencement date of the following therapy.  Consecutive entries for certain disease modifying therapies were merged into a continuous treatment entry, given that the gap between the entries did not exceed 190 days for mitoxantrone, 365 days for cladribine, 90 days for other disease modifying therapies. The default duration of treatment effect was recorded as 190 days (mitoxantrone), 5 years (alemtuzumab) or 365 days (cladribine) from treatment commencement.
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